Information Provided By: 
Fly News Breaks for November 15, 2017
CRME
Nov 15, 2017 | 07:44 EDT
Canaccord analyst Dewy Steadman lowered his price target on Cardiome to $5 from $8 following Q3 results that came in light on revenues due to timing issues. The analyst said he is not concerned abut the near-term weakness but he lowered his long-term peak revenue expectations for several products. Steadman remains positive on the absolute growth potential in Cardiome's overlooked European markets and he reiterated his Buy rating on Cardiome shares.
News For CRME From the Last 2 Days
There are no results for your query CRME
